{"schema_version":"secwatch.filing_event.v1","accession":"0000950103-23-005425","form_type":"8-K","ticker":"PGEN","cik":"0001356090","company_name":"PRECIGEN, INC.","filed_at":"2023-04-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.546312+00:00","generated_at":"2026-06-17T05:44:29.449537+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Precigen enters amended license with Alaunos for TCR products; Alaunos pays $75K annual fee","bullets":["Precigen grants Alaunos exclusive, worldwide, royalty-free license for T-cell receptor products targeting neoantigens and HPV.","Alaunos also gets exclusive license for Sleeping Beauty technology for TCR products for neoantigens and shared antigens.","Alaunos pays $75,000 annual license fee; no milestones or royalties on products.","Alaunos loses rights to IL-12, CAR (CD-19, BCMA), and Gorilla IL-12 products; Precigen retains those.","Precigen may develop products outside the exclusive license; Alaunos can terminate on country/program basis."],"urls":{"canonical":"https://secwatch.observer/filing/0000950103-23-005425","json":"https://secwatch.observer/filing/0000950103-23-005425.json","markdown":"https://secwatch.observer/filing/0000950103-23-005425.md","text":"https://secwatch.observer/filing/0000950103-23-005425.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1356090/000095010323005425/0000950103-23-005425-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1356090/000095010323005425/dp191956_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T05:44:29.449537+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cb3e8524369cb8eae30f75caf72daeb54fa2c643","claim":"PRECIGEN, INC. amended License Agreement with Alaunos Therapeutics valued at $75,000 (effective 2023-04-03).","evidence_excerpt":"On April 3, 2023, Precigen, Inc., (the “Company”), entered into an amended and restated exclusive license agreement (the “License Agreement”), with Alaunos Therapeutics (“Alaunos”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1356090/000095010323005425/0000950103-23-005425-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Alaunos Therapeutics"},{"label":"Value","value":"$75,000"},{"label":"Effective","value":"2023-04-03"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}